Sentences with phrase «of generic drugs in»

Whether or not it was envisioned at the time, the use of generic drugs in the US has seen a tremendous increase since the enactment of the Act.

Kocher speculates that Amazon could reduce costs by accepting lower margins than pharmacy benefits managers — intermediaries that now make huge profits through sales of generic drugs in particular.

The chairman of Apotex, the largest producer of generic drugs in Canada, came under fire recently for helping to organize a $ 500 - per - ticket pay - for - access fundraiser for the party.

Not exact matches

For one thing, «There are a lot of good drugs on the market for heart disease right now that come in generic form,» says Neil Lesser, a principal at Deloitte who specializes in the life sciences, in an interview with Fortune.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Walgreens had forecast that the prices of generic drugs would fall — only to realize that in fact they were rising.

After fighting unsuccessfully to reverse generic drug laws last year, and the sudden resignation of its CEO, Shoppers Drug Mart has suffered a 17 % drop in «brand value,» to $ 2.6 billion, according to a study conducted by researcher Interbrdrug laws last year, and the sudden resignation of its CEO, Shoppers Drug Mart has suffered a 17 % drop in «brand value,» to $ 2.6 billion, according to a study conducted by researcher InterbrDrug Mart has suffered a 17 % drop in «brand value,» to $ 2.6 billion, according to a study conducted by researcher Interbrand.

However analysts point to a bounce in Teva's shares over the past four months and a slowing in the rate of decline of U.S. generic drug prices as bright spots.

Canada's generic drug king found himself on the wrong side of several shaking fingers in the past year.

Making matters worse, Teva was saddled with $ 35 billion debt from its $ 40.5 billion purchase in 2016 of Allergan's generic drug business Actavis, forcing it to sell assets.

Another bright spot could be the slowing in the decline of U.S. generic drug prices, according to report from Credit Suisse, citing data from health information company IQVIA.

Teva said in a statement it would soon start producing a generic version of the drug that will be «priced significantly lower than Viagra,» which will result in «millions in savings to consumers» and «make this medication accessible to people who might otherwise not have been able to afford it.»

The reason there's no generic Viagra yet is because Pfizer, the company that makes it, holds two patents for the drug: the first for Viagra's composition — which expired in 2012 — and the second for what's called a «method of treatment,» meaning how the drug is used.

In general, generics are a wonderful thing — they're a lower - cost alternative to expensive, brand - name versions of drugs.

In a striking move, the Food and Drug Administration has published a list of off - patent drugs which have lost exclusivity and don't have any approved generic versions.

Plus, a handful of companies will typically all get approved to make a generic at once, which ideally creates competition in the marketplace and can sometimes result in even lower prices for those drugs.

Daiichi Sankyo's press release comes in the wake not only of Ranbaxy's highly unusual criminal guilty plea and $ 500 million in fines and penalties — the largest ever against a generic - drug maker — but also a lengthy Fortune article that exposed for the first time the depth and extent of the fraud charges leveled at the company and the knowledge of senior company executives.

Nothing about the drug has changed in that time, and the fact that it's generic flies in the face of the argument that lack of generic competition is the reason for drastic price hikes.

The article described how an internal investigation conducted by a company executive, Dinesh Thakur, who went on to become a whistleblower, reported appalling deceit: Ranbaxy scientists substituted cheaper, lower - quality ingredients in place of better ingredients, manipulated test parameters, and even bought brand - name drugs and used them in place of their own generics to win FDA approval.

These former employees also report being directed to alter physician - written prescriptions so pharmacies would have to dispense Valeant drugs instead of cheaper generic versions in order to maximize Valeant's profits.»

After generic drug maker Actavis bought Allergan last year, it took the name of the specialty pharmaceutical company; the reinvented Allergan then turned around and sold its legacy generic business to Teva Pharmaceutical Industries (TEVA) in July.

The companies have begun to market their «biosimilar» (a generic version of expensive biologic drugs) of Remicade — a copycat of J&J's best - selling rheumatoid arthritis and immunology treatment (which garnered more than $ 5 billion in U.S. sales last year) and was approved by the Food and Drug Administration (FDA) in April — at a striking 35 % discount to its list price.

CVS said it achieved this in part by excluding Valeant diabetes drug Glumetza from its standard formulary, or the list of drugs typically covered by insurance, because a generic version of the medication was available.

According to the GAO report, 71 percent of all generic injectable cancer drugs sold in 2008 were produced by just three manufacturers, while 91 percent of the market share of injectable nutrients and supplements was held by just three pharmaceutical firms.

• Mallinckrodt (NYSE: MNK) is exploring a sale of its generic drug unit in a deal that could fetch as much as $ 2 billion, according to Reuters.

Generic drug giant Teva really is going to cut tens of thousands of jobs in a gigantic restructure for the struggling and debt - laden pharmaceutical — in fact, the 14,000 planned layoffs announced Thursday actually surpass initial reports.

Jean Coutu has a network of 417 franchised stores in Quebec, New Brunswick and Ontario under several banners including PJC Jean Coutu as well as a subsidiary that makes generic drugs.

JERUSALEM — Israeli generic drug maker Teva Pharmaceutical Industries on Thursday said first - quarter earnings surged over 80 percent and raised its outlook for the rest of the year, citing progress in an aggressive restructuring plan.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The whole industry faces turmoil with the advent of laws in several provinces demanding lower prices on generic drugs.

After graduating from the University of Calcutta in 1982, Dilip Shanghvi started working at his father's wholesale generic - drugs business, where he saw an opportunity to manufacture Lithosun, a drug that treated manic - depressive disorders and was unavailable in much of eastern India.

In Ontario, where the drug reforms began, reimbursements for all generics are down to 25 % of the branded price.

In fact, you can save up to 52 percent on the daily costs of your medications if you purchase generic drugs instead of branded ones.

The two heavyweight CEOs were there — along with Jeff Watson, the president of Apotex, Canada's largest generic - drug producer — to present a plan calling for a vast expansion of the role pharmacists play in the Canadian health - care system.

FILE PHOTO: A building belonging to generic drug producer Teva, Israel's largest company with a market value of about $ 57 billion, is seen in Jerusalem March 23, 2010.

Deals between pharmaceutical corporations and their generic drug competitors, which government officials say keep cheaper forms of medicine off the market, can sometimes be illegal and therefore can be challenged in court, the Supreme Court said Monday...

The potential deal would also double down on Fresenius» existing presence in drugs that are injected and deepen its pipeline of new generic drugs.

WASHINGTON (AP)-- The Supreme Court on Wednesday considered a drug company's fight to keep a generic version of its biotech drug off the market for an additional six months that would mean billions more in sales and higher costs to the public.

Bain and Cinven, who earlier this year took control of Germany's Stada, are hoping to use the Merck unit as a buy - and - build platform for Stada, which makes generic drugs and consumer care products and had annual revenues of more than 2 billion euros in 2016, the sources said.

Teva beats first - quarter expectations but still has the same old problems Copaxone's market share and new generic launches helped Teva to forecast - beating profit and revenue but problems persistTeva had to make pricing concessions on its flagship multiple sclerosis drug Copaxone, and now expects a delay in approval of a key migraine drug, fremanezumab.

An Abbreviated New Drug Submission (ANDS) must be approved by Health Canada, the country's federal department in charge of national health care, under Canada's Food and Drug regulations before the generic drug can be marketed in the counDrug Submission (ANDS) must be approved by Health Canada, the country's federal department in charge of national health care, under Canada's Food and Drug regulations before the generic drug can be marketed in the counDrug regulations before the generic drug can be marketed in the coundrug can be marketed in the country.

In April, it announced it was pulling out of the agreement to acquire the generic drug specialist.

The sale process for Mallinckrodt's generic drug business comes amid a wave of dealmaking in the sector.

(Reuters)- Mallinckrodt Plc (MNK.N) is exploring a sale of its generic drug unit, in a deal that could fetch as much as $ 2 billion and help pivot the specialty pharmaceutical maker toward higher - margin branded drugs, according to people familiar with the matter.

A federal judge in Delaware on Friday struck down key patents held by Acorda related to Ampyra, opening the doors for generic versions of the drug by companies including Mylan Inc (MYL.O) and Roxane Laboratories Inc..

But it has been under pressure in the past 12 months due to greater competition from generic drugs and debt from its $ 32 billion acquisition of Baxalta in 2016, a widely criticized deal.

McKesson is primarily engaged in the distribution of generic pharmaceutical drugs, but it also has a technology segment that provides business solutions to a variety of specialty practices.

Roche's drug, Valium, has been available on the market now for regarding forty five many years, and of course is currently in its generic variety, Diazepam.

Leave all medications and drugs in their original, labelled containers with the name of either the pharmacy that dispensed the medication or the manufacturer of the medication, and have on hand a copy of the original prescription, with both the generic and trade names of the drug.

Drugs cited in Tables 1 through 7 are listed in alphabetical order by generic name; brand names are available from the current Physicians» Desk Reference, 23 USP DI 2001: Drug Information for the Health Care Professional, Volume I, 24 and USP Dictionary of USAN and International Drug Names.25 The reference list is not inclusive of all articles published on the topic.